
Eviogen Discovery Private Limited
Bengaluru, India eviogen.com From their website, Nov 2026
Work here? Claim this listing
About
Eviogen Discovery Private Limited is a contract research organization in Bangalore, India. It provides integrated drug discovery, biology, chemistry, DMPK, antibody, cell line, and protein services for pharma, biotech, life-science, and research organizations. It supports projects from target discovery and validation through lead selection and pre-clinical to clinical stages.
Services
Discovery biology
Integrated drug discovery and screening support including target identification, target validation, in-vitro and in-vivo model development, ADMET, pharmacology, toxicology, and protein expression/purification.
Assays & in vitro testing
Assay biology (in vitro)
Cell-free and cell-based assay services against different therapeutic target classes for target validation and mechanism studies.
Assays & in vitro testing
DMPK
In vitro ADME and DMPK services including metabolism, permeability, transporters, solubility, physicochemical properties, protein binding, PK, and bioanalysis.
ADME, DMPK & toxicology
In vitro ADMET
Screening assays covering solution properties, drug absorption and transport, metabolic stability and identification, drug-drug interactions, and in vitro toxicity.
ADME, DMPK & toxicology
Custom antibody development
Polyclonal and monoclonal antibody development, purification, labeling, and single B-cell cloning and lead antibody identification.
Assays & in vitro testing
Clone development and stable cell line generation
Mammalian clone development and stable cell line generation for recombinant proteins, biosimilars, and novel biologics, including characterization and scale-up.
Discovery chemistry
Integrated chemistry, biology, and analytical support for compound design, synthesis, testing, PROTAC chemistry, SAR generation, and lead optimization.
Integrated drug discovery services
Provides integrated drug discovery support from target discovery to lead candidate selection, with flexible FFS or FTE business models.
14 more services
- Assay biology
- Small molecule discovery
- PROTAC discovery
- Screening services
- Biologics services
- PK & immunogenicity
- CAR-T & iPSC services
- CRISPR-Cas9 services
- Antibody drug conjugate services
- SPR analysis
- Antibody hybridoma services
- Sequencing services
- Protein expression and purification
- Cosmetic claim studies
- Turnaround
- 3 weeks to 10 weeks
- What to send
- Polyclonal antibody development: minimum 5 mg of antigen at ≥0.5 mg/mL concentration
- Antigen affinity chromatography requires antigen
Capabilities
- Assays and studies
- In vivo
- Antibodies
- ADME
- SPR
- ADCs
- Cell therapy
23 more
- High-content imaging
- CRISPR
- Hybridoma
- Immunogenicity
- Cell-free assays
- Cell-based assays
- Target validation
- Mechanism studies
- In vitro metabolism
- In vitro permeability
- Transporter assays
- Solubility
- Physicochemical properties
- Protein binding
- Bioanalysis
- PK/PD
- Enzyme inhibition
- CYP induction
- Luminescence
- TR-FRET/HTRF
- Fluorescence polarization
- Absorbance
- AlphaLISA
- Scale and capacity
- Cryopreservation of up to 20 clones per month
- Scaled antibody production (50-100 mL)
- From shake flasks to 2,000L bioreactors
- Target Gene to Master Cell Bank in 6 months
- DNA to production clone under 30 weeks
- Therapeutic areas
- Inflammation
- Oncology
- Immuno-oncology
- Metabolic diseases
- Fibrosis
- Autoimmune disorder
- Infection
Instruments and platforms
- SPR (Biacore)
- WES Protein Simple
- AlphaLISA
- AlphaScreen
- TR-FRET
- HTRF
5 more
- NanoBRET
- High Content Imaging
- Flow Cytometry
- Next Generation Sequencing
- Biacore
Modalities and species
- Modalities
- Small molecule
- Antibody
- ADC
- Peptide
- Cell therapy
- Gene editing
- Recombinant protein
- Biosimilar
- Species and models
- Rabbit
- Chicken
- Mouse
- CHO
- HEK293
- PBMCs
9 more
- Patient derived primary cells
- iPSCs
- Immortalized primary cell line
- Reporter cell lines
- Recombinant protein
- Transient/stable cell line
- Mammalian cell lines
- Animal/human PBMCs
- Immune cells isolated from PBMCs
Industries served
- Pharma
- Biotech
- Life-science
- Research organizations
- Biopharma
- Pharmaceutical
Company
- Type
- CRO
- Founded
- 2016
- Quality
- CPCSEA (animal procedures for monoclonal antibody production) · WHO (documentation aligned with cell line generation) · ICH (documentation aligned with cell line generation) · CDSCO (documentation aligned with cell line generation)
Locations
- Based in
- Bengaluru, India
- Sites
- Bangalore, India
- Serves
- Global
Contacts
- Phone
- +91-8527201536